We bring innovative solutions to pharma and biotech companies global drug development needs. From early development through to registration and post licencing, we deliver both strategic leadership and operational execution of development programmes, covering clinical, regulatory, drug safety, and commercial elements.
Our teams of physicians, scientists and regulatory experts, help clients select the most promising drug candidates and bring them to the market. We guide our clients through their decision making from first in man studies to proof of concept and pivotal trials, regulatory submissions and product launches.
In the last decade, tranScrip has supported over 250 clients and has been integral to many development programmes and regulatory submissions, bringing products to the market each year across a wide range of therapeutic areas.
Our teams of physicians, scientists and regulatory experts work across a wide range of therapy areas. We lead and support many projects in oncology, immunology, infectious diseases and CNS, just to name a few. We have a lot of experience in advanced therapies and areas of high unmet medical need, including many orphan or rare diseases.
Integration with our clients
tranScrip’s key strength besides our in depth understanding of drug development is the ability to rapidly deploy multi-functional teams that provide strategic direction and operational support to a variety of projects, ranging from specific clinical or regulatory issues to coordinating large development programmes.
We are able to ramp up our teams during periods of intense activity and pull away when we are not needed, giving our clients maximum flexibility and avoiding unnecessary fixed costs.
We develop longstanding relationships with our pharma and biotech clients and bolt our teams into theirs seamlessly.
While tranScrip works for several of the top 50 pharma companies, many of the truly innovative early development projects come to us from small biotech’s, often operating virtually and requiring substantial support.